Eli Lilly and Company (ETR:LLY)
Germany · Delayed Price · Currency is EUR 728.20
-8.20 (-1.11%)
Oct 10, 2025, 5:35 PM CET
Eli Lilly and Company Employees
Eli Lilly and Company had 47,000 employees as of December 31, 2024. The number of employees increased by 4,000 or 9.30% compared to the previous year.
Employees
47,000
Change (1Y)
4,000
Growth (1Y)
9.30%
Revenue / Employee
€964,878
Profits / Employee
€250,013
Market Cap
643.72B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 47,000 | 4,000 | 9.30% |
| Dec 31, 2023 | 43,000 | 4,000 | 10.26% |
| Dec 31, 2022 | 39,000 | 4,000 | 11.43% |
| Dec 31, 2021 | 35,000 | 0 | - |
| Dec 31, 2020 | 35,000 | 1,375 | 4.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Healthineers AG | 72,000 |
| Merck KGaA | 59,020 |
| Bayer Aktiengesellschaft | 91,864 |
| Fresenius SE & Co. KGaA | 176,486 |
| Sartorius Aktiengesellschaft | 13,528 |
| Fresenius Medical Care AG | 111,513 |
| Fielmann Group AG | 24,363 |
| Carl Zeiss Meditec AG | 5,730 |
Eli Lilly and Company News
- 16 hours ago - Should Investors Buy Eli Lilly Stock? - The Motley Fool
- 1 day ago - Smart Money Is Betting Big In LLY Options - Benzinga
- 1 day ago - Notable ETF Outflow Detected - IVV, LLY, V, ORCL - Nasdaq
- 1 day ago - Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - Reuters
- 2 days ago - A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Heres Who It Is. - Barron's
- 2 days ago - A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly Stock A Buy? - Forbes
- 2 days ago - AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025? - Nasdaq
- 2 days ago - Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market - The Motley Fool